Catalent (CTLT)
(Delayed Data from NYSE)
$56.41 USD
+0.25 (0.45%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $56.41 0.00 (0.00%) 5:32 PM ET
5-Strong Sell of 5 5
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 121 - 140 ( 217 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Tools: Hard and Soft Landings for COVID-19 Diagnostics and Vaccines
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Higher Growth at a Discount; Raise PT from $120 to $142
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Bioproduction: ''Guten Morgan Europe'' - Positive 2021 Industry Guides from Lonza and Sartorius
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Tools: DC Never Friendlier with Biden "American Rescue Plan"
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
D.C. Very Friendly with Biden "American Rescue Plan";
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Modeling COVID-19: Vaccine and Diagnostic Demand Outlook with Herd Immunity in 2021
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Assuming Co-Coverage and Upgrading to OW: ''Thermoesque'' Biologics Transformation
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department